Investment
Features
FeesSafety
Academy
More
Pluang+

Renforth intersects high-grade gold in new drillholes at Parbec deposit, Quebec, boosting resource potential.

Market News
19 Oct 2026
TheNewswire
View Source
Bullish
Renforth intersects high-grade gold in new drillholes at Parbec deposit, Quebec, boosting resource potential.

Renforth Resources reported successful gold intersections in two drillholes at its Parbec gold deposit in Malartic, Quebec, within the 2025 Mineral Resource Estimate (MRE) pit shell. Highlights include 15.68 g/t Au over 0.85m and 9.41 g/t Au over 4.05m, confirming gold presence in previously untested areas. These results will be used to update the MRE with a current gold price and incorporate historic surface data, potentially increasing resource estimates. The company plans further exploration at Parbec and its Victoria polymetallic deposit, aiming to advance both projects strategically located near the Canadian Malartic mine.

Renforth Resources' recent gold drilling results provide context for readers following basic materials. For readers following basic materials, here is Pluang's market snapshot as of Oct 19, 2026 17:11 WIB: Among 83 priced US basic materials stocks tradable on Pluang, 42 rose and 27 fell today. Notable movers include MP Materials at USD 40.84 (+1.67%), Century Aluminum Company Common Stock at USD 35.59 (+1.60%), and Teck Resources at USD 63.63 (-1.53%).

More News

Lexeo Therapeutics to host event on clinical measures in PKP2 arrhythmogenic cardiomyopathy

Lexeo Therapeutics to host event on clinical measures in PKP2 arrhythmogenic cardiomyopathy

Lexeo Therapeutics announced an educational event on October 21, 2026, focusing on clinical endpoints and outcome measures in PKP2 arrhythmogenic cardiomyopathy (PKP2-ACM). The event will feature discussions by Lexeo's Chief Medical Officer and a lea...

Others
Neutral
14 minutes ago
EyePoint's DURAVYU misses primary endpoint in wet AMD trial but shows reduced treatment burden and safety.

EyePoint's DURAVYU misses primary endpoint in wet AMD trial but shows reduced treatment burden and safety.

EyePoint announced that its DURAVYU treatment for wet age-related macular degeneration (wet AMD) did not meet the primary goal of matching the visual improvement of the standard aflibercept treatment in the LUCIA Phase 3 trial. However, DURAVYU demon...

Company Fundamentals
Neutral
14 minutes ago
Marker Therapeutics wins $2.6M FDA grant to advance MT-601 therapy for pancreatic cancer.

Marker Therapeutics wins $2.6M FDA grant to advance MT-601 therapy for pancreatic cancer.

Marker Therapeutics has been awarded a $2.6 million grant from the FDA's Orphan Products Clinical Trials program to support a Phase 1 study of its MT-601 multi-antigen recognizing T cell therapy for locally advanced unresectable pancreatic cancer. Th...

Market News
Bullish
14 minutes ago
Agility Robotics appoints Mark Vale as audit committee chair ahead of public listing.

Agility Robotics appoints Mark Vale as audit committee chair ahead of public listing.

Agility Robotics announced that Mark Vale, former UPS president and current CEO of Transportation Insight, will join its board and chair the audit committee after its merger with Churchill Capital Corp XI. Vale's extensive experience in global logist...

Company Fundamentals
Bullish
14 minutes ago
JazzCash wins Silver Award for innovation in InsurTech at Money20/20 USA 2026

JazzCash wins Silver Award for innovation in InsurTech at Money20/20 USA 2026

JazzCash, Pakistan's leading digital financial services platform, won the Silver Award in the Banking – InsurTech category at Money20/20 USA 2026 for its health-protection platform Sehat+. This platform provides affordable health insurance to Pakista...

Market News
Bullish
14 minutes ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App